- Home
- EHAB vs SIGA Comparison
EHAB vs SIGA Comparison
Compare EHAB & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- SIGA
- Stock Information
- Founded
- EHAB 2014
- SIGA 1995
- Country
- EHAB United States
- SIGA United States
- Employees
- EHAB N/A
- SIGA N/A
- Industry
- EHAB Hospital/Nursing Management
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- SIGA Health Care
- Exchange
- EHAB Nasdaq
- SIGA Nasdaq
- Market Cap
- EHAB 401.6M
- SIGA 422.9M
- IPO Year
- EHAB N/A
- SIGA 1997
- Fundamental
- Price
- EHAB $9.30
- SIGA $6.12
- Analyst Decision
- EHAB Hold
- SIGA
- Analyst Count
- EHAB 3
- SIGA 0
- Target Price
- EHAB $8.50
- SIGA N/A
- AVG Volume (30 Days)
- EHAB 422.7K
- SIGA 410.3K
- Earning Date
- EHAB 08-05-2025
- SIGA 07-31-2025
- Dividend Yield
- EHAB N/A
- SIGA 9.80%
- EPS Growth
- EHAB N/A
- SIGA N/A
- EPS
- EHAB N/A
- SIGA 0.67
- Revenue
- EHAB $1,032,300,000.00
- SIGA $120,330,310.00
- Revenue This Year
- EHAB $4.66
- SIGA N/A
- Revenue Next Year
- EHAB $4.99
- SIGA $95.31
- P/E Ratio
- EHAB N/A
- SIGA $9.12
- Revenue Growth
- EHAB N/A
- SIGA N/A
- 52 Week Low
- EHAB $6.85
- SIGA $4.95
- 52 Week High
- EHAB $10.91
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- EHAB 36.86
- SIGA 49.66
- Support Level
- EHAB $10.65
- SIGA $5.86
- Resistance Level
- EHAB $10.91
- SIGA $6.63
- Average True Range (ATR)
- EHAB 0.31
- SIGA 0.25
- MACD
- EHAB -0.21
- SIGA 0.00
- Stochastic Oscillator
- EHAB 1.88
- SIGA 33.77
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.